MBC-11 is bone resorption factor inhibitor potentially for the treatment of bone lesions, caused by multiple myeloma, metastatic breast and prostate cancer. MBC-11 reduced the incidence of bone metastases to 40%. MBC-11 also significantly decreased bone tumor burden compared to PBS- or zoledronate-treated mice. References: Reinholz MM, Zinnen SP, Dueck AC, Dingli D, Reinholz GG, Jonart LA, Kitzmann KA, Bruzek AK, Negron V, Abdalla AK, Arendt BK, Croatt AJ, Sanchez-Perez L, Sebesta DP, Lonnberg H, Yoneda T, Nath KA, Jelinek DF, Russell SJ, Ingle JN, Spelsberg TC, Dixon HB, Karpeisky A, Lingle WL. A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites. Bone. 2010 Jul;47(1):12-22. doi: 10.1016/j.bone.2010.03.006. PubMed PMID: 20233612; PubMed Central PMCID: PMC2892200.

纯度：≥98%

CAS：332863-86-2